Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Johnnie J. Orozco, MD, PhD, Aimee Kenoyer, Amanda Axtman, Shani L. Frayo, BS, Paul J. Morris, Donald K. Hamlin, D. Scott Wilbur, PhD, Darrell R. Fisher, PhD, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Ted Gooley, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2011) 118 (21): 3636.

https://doi.org/10.1182/blood.V118.21.3636.3636

Published: 2011

Journal Articles

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

John M. Pagel, Aimee L. Kenoyer, Tom Bäck, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Steven I. Park, Shani Frayo, Amanda Axtman, Nural Orgun, Johnnie Orozco, Jaideep Shenoi, Yukang Lin, Ajay K. Gopal, Damian J. Green, Frederick R. Appelbaum, Oliver W. Press

Blood (2011) 118 (3): 703–711.

https://doi.org/10.1182/blood-2011-04-347039

Published: 2011

Journal Articles

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Steven I. Park, Jaideep Shenoi, John M. Pagel, Don K. Hamlin, D. Scott Wilbur, Nural Orgun, Aimee L. Kenoyer, Shani Frayo, Amanda Axtman, Tom Bäck, Yukang Lin, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, Oliver W. Press

Blood (2010) 116 (20): 4231–4239.

https://doi.org/10.1182/blood-2010-05-282327

Published: 2010

Journal Articles

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Steven I. Park, MD, Jaideep Shenoi, MD, John M. Pagel, MD, PhD, Donald K. Hamlin, Nural Orgun, Aimee L. Kenoyer, Shani M. Wilbur, BS, Amanda Axtman, D. Scott Wilbur, PhD, Yukang Lin, PhD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2009) 114 (22): 2705.

https://doi.org/10.1182/blood.V114.22.2705.2705

Published: 2009

Journal Articles

Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.

Aimee L. Kenoyer, BS, Oliver W. Press, MD, PhD, Steven I. Park, MD, Tom Back, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Darrell R. Fisher, PhD, Shani M. Wilbur, BS, Amanda Axtman, BS, Nural Orgun, Yukang Lin, PhD, Ajay K. Gopal, MD, Jaideep Shenoi, MD, Damian J. Green, MD, Frederick R Appelbaum, John M. Pagel, MD, PhD

Blood (2009) 114 (22): 1035.

https://doi.org/10.1182/blood.V114.22.1035.1035

Published: 2009

NARROW

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.

Email alerts

ASH Publications

American Society of Hematology

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only